Natera Advances Precision Oncology With New Austin Sequencing Hub
Austin, Texas, USA – May 21, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision medicine,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Austin, Texas, USA – May 21, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision medicine,...
SAN DIEGO, Calif., May 19, 2026 Rancho BioSciences has officially launched OmicsHQ™, a comprehensive and expertly curated multi-omics data...
SOUTH SAN FRANCISCO, Calif., May 2026 Mission Bio announced new data demonstrating the power of its Targeted Single-Cell DNA+RNA...
EMERYVILLE, CALIFORNIA, April 29, 2026 Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to...
BOSTON, April 16, 2026 Foundation Medicine, Inc. has announced a major expansion of its oncology diagnostics portfolio through the...
Fremont, California | April 13, 2026 Personalis, Inc. has unveiled new data showcasing its ultrasensitive ctDNA-based cancer monitoring platform,...
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to...
IRVING, Texas, USA — April 1, 2026 Caris Life Sciences® has announced the launch of Caris ChromoSeq™, the world’s...
